Context Therapeutics receives FDA Fast Track for CTIM-76 in platinum-resistant ovarian cancer

Context Therapeutics Inc.

FDA granted Fast Track Designation for CTIM-76 (CLDN6 x CD3 bispecific antibody) in PROC after all standard therapies.
Phase 1a trial evaluating CTIM-76 in CLDN6-positive ovarian, endometrial, and testicular cancers is ongoing.
Interim data from the Phase 1a trial expected in June 2026.
Fast Track aims to expedite development and review for serious conditions with unmet need.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.